<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00222976</url>
  </required_header>
  <id_info>
    <org_study_id>Bio-REB 05-96</org_study_id>
    <nct_id>NCT00222976</nct_id>
  </id_info>
  <brief_title>Oral vs Rectal Admin of Naproxen for Post-Vag Perineal Pain Control</brief_title>
  <official_title>Oral vs Rectal Administration of Naproxen for Post-Vaginal Perineal Pain Control: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Saskatoon Health Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether the route of administration of&#xD;
      naproxen (either by mouth or rectally) influences post-vaginal delivery perineal pain&#xD;
      control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postpartum perineal pain is common after vaginal delivery. Naproxen suppositories have been&#xD;
      shown to be effective at reducing postpartum perineal pain. To date, no studies have&#xD;
      investigated the efficacy of oral naproxen for perineal pain control. Currently, rectal&#xD;
      naproxen is used postpartum because of an assumption that there is a &quot;local effect&quot; compared&#xD;
      to oral administration. However, this effect has never been documented in the literature.&#xD;
&#xD;
      Principles of pharmacology dictate that the least invasive route of drug administration&#xD;
      should be used when two or more routes are equally effective. If oral and rectal naproxen are&#xD;
      equally efficacious at controlling post-vaginal delivery perineal pain, then current practice&#xD;
      would be challenged.&#xD;
&#xD;
      The primary objective of this study is to determine whether the route of administration of&#xD;
      naproxen influences post-vaginal delivery perineal pain control. Pain scores will be measured&#xD;
      using a visual analog scale. The secondary outcome measures are three-fold: patient&#xD;
      preference of route of administration, medication adverse effects, and additional requests&#xD;
      for analgesia. The working hypothesis is that there is no difference in pain control between&#xD;
      oral and rectal administration and that patients will prefer the oral route.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>post-vaginal delivery perineal pain scores will be measured using a visual analog scale.</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient preference of route of administration</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>medication adverse effects</measure>
    <time_frame>until completion of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>additional requests for analgesia.</measure>
    <time_frame>until completion of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Post-Vaginal Delivery Perineal Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A Naproxen PO + placebo PR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B Placebo PO + Naproxen PR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Treatment allocation either A Naproxen PO + placebo PR or B Placebo PO + Naproxen PR</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Potential volunteers who meet all of the following criteria are eligible for this&#xD;
             study:&#xD;
&#xD;
               1. Active labor, whether spontaneous or induced&#xD;
&#xD;
               2. Age between 18 and 40 years old&#xD;
&#xD;
               3. Nulliparous&#xD;
&#xD;
               4. BMI &lt; 40&#xD;
&#xD;
               5. Single live intrauterine fetus in cephalic presentation&#xD;
&#xD;
               6. Term gestation (370 weeks to 416 weeks inclusive) as defined by ultrasound or&#xD;
                  last menstrual period dating&#xD;
&#xD;
               7. Intrapartum epidural labour analgesia&#xD;
&#xD;
               8. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Potential volunteers meeting one of more of the following criteria may not be&#xD;
             enrolled:&#xD;
&#xD;
               1. Medical conditions including:&#xD;
&#xD;
                    1. Naproxen, aspirin or other non-steroidal anti-inflammatory drug&#xD;
                       hypersensitivity&#xD;
&#xD;
                    2. Asthma&#xD;
&#xD;
                    3. Peptic ulcer disease or other inflammatory gastrointestinal disease&#xD;
&#xD;
                    4. Renal, hepatic or cardiac disease&#xD;
&#xD;
                    5. Coagulopathy&#xD;
&#xD;
                    6. Rectal or anal pathology including recent (within 1 month) rectal bleeding&#xD;
&#xD;
                    7. Prescribed medications including lithium, furosemide, antihypertensives,&#xD;
                       anticoagulants, aminoglycosides, hydantoins, or sulfonamides&#xD;
&#xD;
               2. Obstetrical conditions including:&#xD;
&#xD;
                    1. Multiple pregnancy&#xD;
&#xD;
                    2. Extensive perineal trauma (third or fourth degree laceration)&#xD;
&#xD;
                    3. Forceps delivery&#xD;
&#xD;
                    4. Cesarean section delivery&#xD;
&#xD;
                    5. Paracervical or pudendal nerve blocks&#xD;
&#xD;
                    6. Vulval or vaginal hematomas&#xD;
&#xD;
               3. Nulliparous women not requiring intrapartum epidural labour analgesia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David C Campbell, MD,MSC,FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesia, Royal University Hospital, University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>September 19, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>November 13, 2007</last_update_submitted>
  <last_update_submitted_qc>November 13, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2007</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

